Related Experiment Videos
Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes
P Raskin1, L Jovanovic, S Berger
1University of Texas Southwest Medical Center, Dallas 75390, USA. praski@mednet.swmed.edu
Diabetes Care
|July 15, 2000
Summary
Combination therapy with repaglinide and troglitazone significantly improved glycemic control in type 2 diabetes patients. This repaglinide/troglitazone combination was more effective than monotherapy, with similar safety profiles.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 2 diabetes mellitus (T2DM) management often requires combination therapy for inadequate glycemic control.
- Previous monotherapies (sulfonylureas, acarbose, metformin) were insufficient for some T2DM patients.
Purpose of the Study:
- To compare the efficacy and safety of repaglinide/troglitazone combination therapy versus monotherapy in T2DM.
- To evaluate repaglinide monotherapy against troglitazone monotherapy.
Main Methods:
- A multicenter, open-label clinical trial involving 256 patients with T2DM and HbA1c ≥7.0%.
- Randomized assignment to repaglinide, troglitazone, or combination therapy over 22 weeks, including titration phases.
- Assessment of changes in HbA1c and fasting plasma glucose (FPG).
Main Results:
- Combination therapy achieved a significantly greater HbA1c reduction (-1.7%) compared to monotherapies.
- Repaglinide monotherapy showed a greater HbA1c reduction (-0.8%) than troglitazone monotherapy (-0.4%).
- Combination therapy led to superior FPG reduction (-80 mg/dl) versus repaglinide (-43 mg/dl) or troglitazone (-46 mg/dl).
Conclusions:
- Repaglinide/troglitazone combination therapy offers superior glycemic control in T2DM compared to individual agent monotherapy.
- Repaglinide monotherapy is more effective than troglitazone monotherapy for lowering HbA1c.
- The combination therapy was effective and well-tolerated, with no unexpected adverse events observed.